Log In
BCIQ
Print this Print this
 

KTN3379

  Manage Alerts
Collapse Summary General Information
Company Kolltan Pharmaceuticals Inc.
DescriptionHuman mAb against erb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)
Molecular Target Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody; Epidermal growth factor (EGF) receptor 3 (HER3) (ErbB3) inhibitor
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today